Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2022 04:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Sends Letter to Rubric Capital Management

LONDON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...
July 05, 2022 16:01 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare...
June 02, 2022 08:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

--ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off-- --Etigilimab safe and well tolerated, no new safety signals-- ...
May 26, 2022 17:05 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable...
May 26, 2022 16:30 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology...
May 17, 2022 08:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology...
May 09, 2022 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period ...
May 06, 2022 17:12 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

LONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology...
April 06, 2022 08:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
March 31, 2022 16:01 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights

LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...